Our team is consistently pursuing innovative research and solutions to help people living with immune-mediated diseases like #UlcerativeColitis find relief. Learn more about an exciting new analysis of our Phase 3 trial evaluating a treatment for adults with moderately-to-severely active ulcerative colitis. Read more in the journal Clinical Gastroenterology and Hepatology. https://bit.ly/4eA8qIP
Exciting progress in ulcerative colitis research! Looking forward to reading more about your Phase 3 trial results.
Daniel Quirk, MD, MPH, MBA Bristol Myers Squibb This is phenomenal. Great work!!